所属 医学部 医学科（東京女子医科大学病院） 職種 講師
|発表タイトル||Haemoglobin A1c (HbA1c) in Diabetic Patients with Myocardial Infarction: Is HbA1c an Independent Risk Factor and Predictor of Adverse Outcome?|
|会議名||The 83rd Annual Scientific Meeting of the Japanese Circulation Society (JCS2019)|
|主催者||Japanese Circulation Society|
|発表者・共同発表者||◎SUZUKI Atsushi, SHIGA Tsuyoshi, OGAWA Hiroshi, HAGIWARA Nobuhisa|
|概要||*Oral Presentation (English)29 Diabetes
The mortality after myocardial infarction (MI) is higher in patients with diabetes mellitus (DM) than without DM. However, the relationship is not clear the glycosylated hemoglobin (HbA1c) level and mortality in patients after MI. We examined the effect of HbA1c on all-cause mortality in Japanese survivors of MI using data from the HIJAMI II. Patients with DM (n=1,041) were categorized into the three HbA1c groups at baseline: HbA1c <7.0% (n=553), 7.0%≤
HbA1c <8.0% (n=198), 8.0%≤ HbA1c (n=290). During an average follow-up of 4.1±1.4 years, all-cause death, cardiovascular (CV) death and sudden cardiac death (SCD) were was 15.9%, 8.2% and 2.0%, respectively. The mean HbA1c in this study was 7.2±1.7%. By Kaplan-Meier analysis, there was not significant difference between 3 HbA1c groups in all-cause mortality, CV death and SCD (Figure). Multivariate analysis revealed that an each HbA1c level was not a significant predictor of all-cause mortality, CV death and SCD in patients with diabetes after MI. The optimal HbA1c levels remains to be elucidated in diabetic patients after MI.